Documents | Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | Guidance | NICE

Documents

A list of downloadable documents created during development.

Final appraisal determination

Final appraisal determination
Final appraisal determination document 06 April 2016 610.33 KB
Committee papers 06 April 2016 2.29 MB

Appraisal consultation

Appraisal consultation
Appraisal consultation document 23 December 2015 513.22 KB
Committee papers 23 December 2015 14.5 MB

Assessment report sent for information

Assessment report 19 October 2015 4.48 MB

Protocol

Protocol 24 March 2015 320.5 KB

Response to comments on scope and matrix

Response to comments on scope and matrix 02 March 2015 256.29 KB

Equality impact assessment form

Equality impact assessment form 02 March 2015 63.79 KB

Final matrix

Final matrix 02 March 2015 101.98 KB

Final scope

Final scope 02 March 2015 105.32 KB

Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy): draft scope (post-referral)

Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy): draft scope (post-referral) 08 July 2014 129.45 KB

Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy): provisional matrix (post-referral)

Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy): provisional matrix (post-referral) 08 July 2014 92.76 KB